---
kind: "section"
citation: "21 C.F.R. § 349.75"
title: "21"
number: "349.75"
heading: "Labeling of ophthalmic vasoconstrictor drug products."
url: "https://uscodex.org/cfr/21/349.75"
---

# §349.75. Labeling of ophthalmic vasoconstrictor drug products.

- (a) **Statement of identity.** The labeling of the product contains the established name of the drug(s), if any, and identifies the product as a “redness reliever” or “vasoconstrictor (redness reliever)” (select one of the following: “eye” or “ophthalmic”) “(insert dosage form, e.g., drops).”
- (b) **Indications.** The labeling of the product states, under the heading “Indications,” the following phrase: “Relieves redness of the eye due to minor eye irritations.”
- (c) **Warnings.** In addition to the warnings in [§ 349.50](/cfr/21/349.50.md), the labeling of the product contains the following warnings under the heading “Warnings” for products containing any ingredient identified in [§ 349.18](/cfr/21/349.18.md):
  - (1) “If you experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours, discontinue use and consult a doctor.”
  - (2) “Ask a doctor before use if you have [in bold type] narrow angle glaucoma.”
  - (3) “Overuse of this product may produce increased redness of the eye.”
  - (4) “If solution changes color or becomes cloudy, do not use.”
  - (5) “When using this product [in bold type] pupils may become enlarged temporarily.”
- (d) **Directions.** The labeling of the product contains the following information under the heading “Directions”: Instill 1 to 2 drops in the affected eye(s) up to four times daily.

## Notes

### Amendments

[53 FR 7090, Mar. 4, 1988, as amended at 65 FR 38428, June 21, 2000]

### Authority

Authority: 21 U.S.C. 321, 351, 352, 353, 355, 360, 371.

### Source

Source: 53 FR 7090, Mar. 4, 1988, unless otherwise noted.

### Amendments

[53 FR 7090, Mar. 4, 1988, as amended at 65 FR 38428, June 21, 2000]